Publication Date
| In 2015 | 0 |
| Since 2014 | 0 |
| Since 2011 (last 5 years) | 1 |
| Since 2006 (last 10 years) | 2 |
| Since 1996 (last 20 years) | 2 |
Descriptor
| Adolescents | 2 |
| Age Differences | 2 |
| Body Weight | 2 |
| Children | 2 |
| Drug Therapy | 2 |
| Mental Retardation | 2 |
| Pervasive Developmental… | 2 |
| Symptoms (Individual… | 2 |
| Adults | 1 |
| Attention Deficit… | 1 |
| More ▼ | |
Source
| Journal of Mental Health… | 2 |
Author
| Hellings, Jessica A. | 2 |
| Schroeder, Stephen R. | 2 |
| Boehm, Danna | 1 |
| Butler, Merlin G. | 1 |
| Cardona, Alicia M. | 1 |
| Yeh, Hung Wen | 1 |
Publication Type
| Journal Articles | 2 |
| Reports - Research | 2 |
Education Level
Audience
Showing all 2 results
Hellings, Jessica A.; Boehm, Danna; Yeh, Hung Wen; Butler, Merlin G.; Schroeder, Stephen R. – Journal of Mental Health Research in Intellectual Disabilities, 2011
We retrospectively reviewed clinic charts of 21 children and adolescents with developmental disabilities including autism spectrum disorders (ASD) treated consecutively with aripiprazole (ARI) for irritability and severe challenging behaviors. Data extracted include age, sex, and race; level of intellectual disability (ID); "Diagnostic and…
Descriptors: Symptoms (Individual Disorders), Body Composition, Mental Retardation, Autism
Hellings, Jessica A.; Cardona, Alicia M.; Schroeder, Stephen R. – Journal of Mental Health Research in Intellectual Disabilities, 2010
The objective of this study was to examine long-term adverse events of risperidone in 19 children, adolescents, and adults with Pervasive Developmental Disorders and intellectual disability, continuing risperidone for a mean of 186.5 weeks, following a 46-week risperidone study. Nineteen individuals continued long-term follow-up after our…
Descriptors: Mental Retardation, Pervasive Developmental Disorders, Drug Therapy, Safety

Peer reviewed
Direct link
